Affinity Asset Advisors »

Silverback Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Silverback Therapeutics (SPRY) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Silverback Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Silverback Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Silverback Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $5.8M 400k 14.50
2022-06-30 $721k 170k 4.24

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Xenon Pharmaceuticals (XENE)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Verona Pharma Sponsored Ads (VRNA)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Nuvalent Inc-a (NUVL)
Spyre Therapeutics Com New (SYRE)
Wave Life Sciences SHS (WVE)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Vera Therapeutics Cl A (VERA)
Nurix Therapeutics (NRIX)

View all positions for Affinity Asset Advisors

Top funds holding Silverback Therapeutics

RA Capital Management
Deerfield Management Company
OrbiMed Advisors
BlackRock
Sr One Capital Management
Alliancebernstein
Vanguard Group
State Street Corporation
Franklin Resources
Alyeska Investment Group
Geode Capital Management
Woodline Partners
Nextech Invest
FMR
Citadel Advisors

View all funds holding Silverback Therapeutics